Neurological Diagnostics News
-
Showcase
VisionQuest Abstract on Diabetic Peripheral Neuropathy Accepted by ADA
We’re looking forward to presenting “Detecting Diabetic Peripheral Neuropathy Utilizing Thermoregulation of the Plantar Foot” at the upcoming 82nd Scientific Sessions of the American Diabetes Association. Our research aims to detect thermal (infrared) biomarkers of diabetic peripheral neuropathy on the feet of diabetic subjects who have not been diagnosed with DPN. By analyzing ...
-
Microneedle Market Projected to Reach $1.3 Billion by 2028, Reveals Latest BCC Research Study
Boston: Microneedle technology, driven by high demand in dermatologic procedures and its versatile applications in drug delivery, vaccine administration, and disease diagnostics, faces challenges in its complex manufacturing process. Ongoing research and numerous products in development make this market dynamic for newcomers entering the field. “According to the latest BCC Research study, ...
By BCC Research
-
Rescale and Caresyntax Expand their Collaboration to Provide Scalable Platform for AI-Powered Simulation and Intelligence in Surgery. World Economic Forum Collaboration Enhances Access to Surgical Care and Contributes to Health Equity
Rescale, the leader in cloud high performance computing (HPC) to accelerate innovation and research, and Caresyntax, the leading vendor-neutral surgical data and intelligence platform converging AI-powered software, devices, and clinical services, announced a broader collaboration through the World Economic Forum Open Forum for AI in Health and Healthcare Communities. This collaboration marks ...
By Caresyntax
-
Synaptive’s Modus X Takes Center Stage in the latest issue of the Journal of Neurosurgery’s Neurosurgical Focus on exoscopes in neurosurgery
January’s Journal of Neurosurgery (JNS) published a series of 17 videos that examine the application of exoscopic visualization in cerebrovascular, neuro-oncologic, pediatric, peripheral nerve, and spinal neurosurgery. The video series highlights the exoscope as a versatile alternative to traditional optical microcopy. Seven of the videos highlight the use of Synaptive’s robotic ...
-
Multi-Type Animal Cognitive Behavioral Tests for Disease Research
In the pursuit of advancing disease research and its treatment, animal cognitive behavior is studied in a wide range of animal species. The innovative multi-type animal cognitive behavioral tests are set to complement disease research methodology, enabling scientists to gain deeper insight into the complexities of cognitive functioning and its implications in various pathological conditions. ...
By Protheragen
-
Animal Emotional Behavior Tests for Anxiety and Depression Treatment
In today’s fast-paced and stressful society, the prevalence of anxiety and depression has become a significant concern. Emotion-related animal behavior tests aim to provide a good research tool for the study of emotion-associated diseases. Anxiety and depression affect millions of individuals worldwide, leading to a significant burden on public health and impacting overall quality of ...
By Protheragen
-
CD Genomics Unveils Cutting-Edge CRISPR Screen Sequencing Technology
CD Genomics, a distinguished leader in genomics and sequencing services, has proudly unveiled its groundbreaking CRISPR Screen Sequencing technology. This innovative solution promises to expedite discoveries, facilitate target identification, and optimize drug development pipelines within the biotechnology and pharmaceutical industries. CRISPR Screen Sequencing, a genome-wide screening ...
By CD Genomics
-
Ionis Announces Fda Acceptance Of New Drug Application For Eplontersen For The Treatment Of Hereditary Transthyretin-Mediated Amyloid Polyneuropathy (Attrv-Pn)
CARLSBAD, Calif., March 7, 2023 /PRNewswire/ -- Ionis Pharmaceuticals (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for eplontersen, an investigational antisense medicine for the treatment of people living with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN). The application has been given ...
-
Emerging Trends in the BioPharma Industry that you Need to Know
Emerging trends in the biopharma industry include new developments in cancer treatments, advances in gene therapy, and more data-driven decision-making. As a leader in the sector, it’s important to be aware of these developments to make informed decisions about your organization’s direction. In this blog post, we’ll explore some of the most significant emerging trends in ...
By Brio Group
-
Bened Biomedical Completes $10M Series A, Set for Expansion into US Healthcare Market
Medical probiotic leader Bened Biomedical Co., Ltd., which develops and markets neuroactive probiotic products, announced a completed Series A round of fundraising, receiving more than $10 million of capital from two prominent investors, Trans-Pacific Technology Fund (TPTF) and JAFCO Asia. With strategic support from these venture capital partners, Bened expects to rapidly expand its ...
-
Liposomal Bupivacaine (Bupigel) Demonstrates Minimal Local Nerve Toxicity in a Rabbit Functional Model
Abstract: We previously reported the development of a novel formulation of an ultra-long-acting local anesthetic based on bupivacaine encapsulated in large multivesicular liposomes (Bupisomes) embedded in hydrogel. This formulation (Bupigel) prolonged bupivacaine release from the formulation in dissolution-like studies in vitro and analgesia in vivo in mouse, rat, and pig models. In this study we ...
-
Teva and MODAG Announce Licensing Collaboration for Neurodegenerative Disease Drug Candidate
TEL AVIV & WENDELSHEIM, Germany--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and MODAG GmbH today announced a strategic collaboration on the exclusive worldwide licensing and development of MODAG's lead compound anle138b and a related compound, sery433. Anle138b targets pathological alpha-synuclein oligomers and is being evaluated in patients with ...
By MODAG GmbH
-
Bayer progressing well with transformation of pharma business and raises peak sales potential of key growth drivers to over twelve billion euros
Strong market uptake of Nubeqa and Kerendia Asundexian projected peak sales of more than five billion euros as treatment option for thrombosis and stroke prevention High-value late-stage development portfolio Positive study outcomes from cell & gene therapy pipeline would provide potential upside Shift of resources enhances commercialization and competitiveness Acquired arm’s ...
By Bayer AG
-
AskBio Announces Strategic Collaboration with ReCode Therapeutics to Explore Single Vector Gene Editing Platform
Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, announced today that it has signed a multi-year research collaboration and option agreement with ReCode Therapeutics. Under this agreement, the companies will work together to potentially discover precision genetic medicines through the development of a novel platform for full gene ...
By Bayer AG
-
Cingulate Initiates Phase 3 Study of Lead Asset CTx-1301, Designed as a True Entire Active-Day Treatment for ADHD
Company to Host Investor and Business Development Meetings Adjacent to Upcoming J.P. Morgan Healthcare Conference in San Francisco Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced the ...
By Cingulate
-
Combines mesenchymal stem-cell-based product, with Kurve’s intranasal drug delivery technology
Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, and Kurve Therapeutics, a next-generation medtech and drug formulation company, today announced positive preclinical study results for intranasal administration of a cell-based oncolytic virus bearing product. The results ...
-
gammaCore Sapphire Non-Invasive Vagus Nerve Stimulator (nVNS) Receives Unique National Product Code Number by the Belgian Pharmaceutical Association
electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that gammaCore Sapphire has been issued a National Code Number (CNK) in Belgium. CNK numbers are unique product code identifiers allocated by the Belgian Pharmaceutical Association (APB) for products and medicines commercially available from pharmacies throughout ...
-
InMed Pharmaceuticals Advances Neurodegenerative Disease Program with Natural Sciences and Engineering Research Council of Canada (`NSERC`) Alliance Grant Funding
Targeting neurodegenerative diseases such as Alzheimer’s, Huntington’s and Parkinson’s Identified two lead cannabinoid analog compounds for in vivo studies NSERC grant funding supports InMed’s collaborative research projects with Dr. Kumar from University of British Columbia (UBC) VANCOUVER, British Columbia, Nov. 16, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals ...
-
electroCore to Participate at Canaccord Genuity MedTech and Diagnostics and Digital Health & Services Forum
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that electroCore’s Chief Executive Officer, Dan Goldberger, will be conducting one-on-ones at the Canaccord Genuity MedTech and Diagnostics and Digital Health & Services Forum. Canaccord Genuity MedTech and Diagnostics and Digital Health & Services Forum Date: Thursday, November ...
-
Differences Between Spinal Blocks & Epidurals
The biggest difference between spinal blocks vs epidurals is their amount of pain relief: spinal blocks provide total pain relief, while epidurals provide partial pain relief. The reason for this difference is that the former is an anesthetic, while the latter is an analgesic—no sensation versus no pain. But pain elimination comes with a total lack of feeling in the lower body, due to ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you